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Approximately 50% of late-onset Alzheimer’s disease (AD) patients develop psychosis (AD+P), a heritable phenotype associated
with more rapid cognitive decline. Prior studies conﬂict regarding whether apolipoprotein E (APOE) 4 alleles are associatedwith
AD+P,possiblydue to smallsamplesizes,inconsistentdiagnosticcriteria,anddiﬀerent methodologiestoassesspsychosis.Weused
the National Alzheimer’s Coordinating Center Uniform Data Set to evaluate the largest uniformly characterized sample of AD+P
subjects studied to date for the association of APOE 4 genotype, along with other demographic and clinical variables. Greater
cognitive impairment and depressive symptoms were associated with AD+P, while the Caucasian race was protective. Neither
APOE 4 carrier status nor allele number was associated with psychosis. The AD+P phenotype is not associated with the APOE
4 genotype. AD+P mayrepresent a useful phenotype for the discovery of non-APOE 4 genetic variation contributing to the risk
of AD.
1.Introduction
Psychotic symptoms, delusions, and hallucinations are com-
m o ni nA l z h e i m e r ’ sd i s e a s e( A D ;A D + P ) ,o c c u r r i n gi n
approximately 40% of individuals over the course of the
illness [1]. AD+P causes signiﬁcant distress for patients and
family members [2]. AD+P is a predictor of worse cognitive
and functional outcome, higher likelihood of institutionali-
zation, and higher mortality rate [3]. Importantly, a number
of studies indicate that the occurrence of psychosis in AD
is familial [4–6], with an estimated heritability of 61%
[7], indicating a distinct neurobiology of this phenotype
[8].
Recently, Ropacki and Jeste [1] comprehensively re-
viewed the literature on psychosis in AD. They reviewed 55
studies comprised of 9,749 subjects. The most consistent
correlate of AD+P was greater cognitive impairment than
is found in AD without psychosis (AD−P). In twenty of
thirty studies which assessed this relationship, the prevalence
of psychosis increased as cognitive impairment worsened
as determined by the Mini Mental State Exam (MMSE).
Studies conducted more recently have continued to support
the relationship between greater cognitive impairment and
AD+P [9, 10]. In contrast, only inconsistent associations
have been detected between AD+P and age, age at onset of
AD, illness duration, gender, and education. AD+P may be
associated with race, though it has only been examined in
a limited number of studies to date [1]. It should be noted
that the above conclusions are limited by the inconsistencies
across the reviewed studies. Few variables are examined
in all studies; sample sizes of individual studies were not
always suﬃcient to detect small-to-moderate eﬀects, and
approaches to characterization of subjects, including iden-
tiﬁcation of psychosis, also varied considerably.2 International Journal of Alzheimer’s Disease
ApolipoproteinE(APOE)iswelldocumentedasbeingan
important genetic determinant for the development of late-
onset AD [11]. However, its association with development
of psychosis is less clear. We have identiﬁed 22 studies
that examined the association of the APOE 4 allele with
AD+P, with nine reporting that 4i n c r e a s e dt h er i s kf o r
AD+P, whereas 13 studies found no eﬀect of 4[ 12].
As in the studies of clinical correlates of AD+P, these
reports varied considerably in their subject populations,
sample sizes, deﬁnitions of AD+P, and analytic approaches,
precluding clear interpretation of the conﬂicting pattern of
results. Moreover, as highlighted by recent genome-wide
association studies, genes of small, but real, eﬀects (e.g., RR
1.1-1.2) often show inconsistent results in studies with small
sample sizes, with the currently recommended sample sizes
numbering in the thousands. Although APOE 4c o n f e r s
greaterrelative riskforAD,itmayhaveasmaller, ifany,eﬀect
on the development of psychosis in AD.
To more reliably determine the correlates of the AD+P
syndrome, it would be desirable to analyze a large cohort of
individuals with late-onset AD who have been characterized
inastandardized manner. Toaccomplishthisgoalweutilized
the Uniform Data Set (UDS) collected by the National
Alzheimer’sCoordinatingCenter(NACC)tocharacterize the
clinicalcorrelates of AD+P. To date, this is the largest data set
used to look at the association of APOE 4w i t hA D + P .W e
hypothesized that the APOE 4 genotype is not associated
with the development of AD+P. We also hypothesized that
AD+P is associated with greater cognitive impairment.
2.Methods
2.1. NACC Data Center. The NACC was developed in 1999
with the purpose of developing and maintaining a database
that included data from NIH-funded Alzheimer’s Disease
Centers (ADC) across the country. The UDS was developed
by NACC to provide the ADCs with standardized assess-
ments thereby allowing uniformity amongst centers when
diagnosing these subjects with mild cognitive impairment
or Alzheimer’s disease [13]. Individual centers may use
additional assessments for their particular research proto-
cols, but every center must complete the UDS assessments
[14]. Since 2005, these have included ratings of psychosis
on the Neuropsychiatric Inventory Questionnaire (NPI-Q)
[15].
2.2. Eligibility Criteria. Subjects were selected for analysis
on the basis of having a primary diagnosis of possible or
probable AD with an age of onset ≥60. Subjects with co-
morbid Parkinson’s disease or dementia with Lewy bodies
were excluded. Additionally, subjects were required to have
available psychosis ratings on the NPI-Q and an APOE
genotype. Other variables requested, but not available for
all subjects, included demographics (age at ﬁrst visit, age
of onset of dementia, sex, race, ethnicity, primary language,
education) and scores on the Mini-Mental State Exam
(MMSE) [16], global Clinical Dementia Rating Scale (CDR)
[17], Hachinski Ischemic Scale [18], and the Geriatric
Depression Scale (GDS) [19]. Because some subjects had
multiple visits over time, for these individuals the last
available scores for MMSE, CDR (global), Hachinski, and
GDS were used for analysis. Regarding race and ethnicity,
subjects reported their race to a clinician from the following
choices: White, Black, or African-American, American-
Indian, or Alaska Native, Native Hawaiian or other Paciﬁc
Islander, Asian, other, or Unknown. From this, subjects were
grouped as Caucasian, African-American, or other for anal-
ysis. Subjects also reported as to whether they had Hispanic/
Latino ethnicity. This study had Institutional Review Board
approval through the University of Pittsburgh and Universi-
ties contributing their data to the NACC.
2.3. Classiﬁcation of Psychosis. Each subject was assessed for
psychosis at each visit using the NPIQ. Informants for the
NPIQ ratings were most commonly a subject’s spouse (2889,
57.7%) or child (1606, 32.1%) and rarely other informants
(515, 10.3%). Subjects were rated positive for psychosis at
any visit if they exhibited delusions (question 1) and/or
hallucinations (question 2) within a one-month time frame
prior to the interview. Subjects with neither item endorsed
at any visit were categorized as Never Psychotic. Subjects
with one item present at no more than one visit were
characterized as having Single Psychosis. Subjects with both
items present at any one visit, or one or more items present
at multiple visits, were characterized as Multiple/Recurrent
Psychosis.
2.4. Statistical Analysis. The association of AD+P with base-
line clinical and demographic variables was analyzed using
univariate (Chi-square and ANOVA, as appropriate) tests.
Wetestedtheassociations ofAD+PwithAPOEgenotypeand
4 carrier statusby Chi-square. Follow-upanalyses of associ-
ation used multinomial logistic regression models, including
APOE genotype, and clinical and demographic variables.
Because MMSE and CDR score are highly correlated, in
these latter analyses we omitted the CDR score. Additional
multinomial logistic regression analyses were conducted
including a main eﬀect of site (24 ADCs contributed to the
data set) but were not reported as they yielded essentially
identical results.
3.Results
We identiﬁed 2317 subjects in the NACC database who
fulﬁlled all eligibility criteria for analysis. Of these subjects,
777 (33.5%) had one visit, 730 (31.5%) had two visits, 485
(20.9%) had three visits, 307 (13.2%) had 4 visits, and 18
(0.8%) had ﬁve visits for a total number of 5010 visits
reported to NACC. The majority of subjects were diagnosed
with probable AD (2117, 91.4%) and the remaining (200,
8.6%)withpossibleAD .Thesamplepredominatelyconsisted
of Caucasian (1957, 84.5%) and female (1309, 56.5%)
subjects (Table 1). The majority of patients were carriers of
the APOE 4 allele (1383, 59.7%) (Table 1).International Journal of Alzheimer’s Disease 3
Table 1: Demographic and clinical characteristics and their associationwith AD+P.
Variable
Psychosis Status Total N (%) or
mean (SD) χ2† or F‡ df P value
Never N (%)
or mean (SD)
Single N (%)
or mean (SD)
Multiple/Recurrent
N (%) or mean (SD)
Age 78.2 (6.8) 79.0 (7.1) 78.3 (7.1) 78.4 (6.9) 2.197‡ .111
Age of onset 73.3 (6.9) 73.4 (7.1) 72.3 (6.9) 73.2 (6.9) 2.862‡ .057
Sex
15.673† 2 <.001 Male 704 (46.5) 188 (38.1) 116 (37.5) 1008 (43.5)
Female 811 (53.5) 305 (61.9) 193 (62.5) 1309 (56.5)
Race
82.409† 4 <.001 Caucasian 1347 (89.0) 394 (80.0) 216 (70.0) 1957 (84.5)
African-American 132 (8.7) 76 (15.4) 69 (22.3) 277 (12.0)
Other 35 (2.3) 23 (4.6) 24 (7.7) 82 (3.5)
Hispanic
21.161† 2 <.001 No 1429 (94.3) 448 (90.9) 270 (87.4) 2147 (92.7)
Yes 86 (5.7) 45 (9.1) 39 (12.6) 170 (7.3)
Primary language
13.100† 2 .001 English 1425 (94.1) 455 (92.3) 273 (88.3) 2153 (92.9)
Other 90 (5.9) 38 (7.7) 36 (11.7) 164 (7.1)
Education 14.2 (3.6) 13.4 (3.6) 13.0 (4.2) 13.8 (3.7) 19.138‡ <.001
MMSE 18.7 (6.7) 16.8 (7.0) 14.2 (7.1) 17.7 (7.0) 59.922‡ <.001
CDR (global)
177.772† 8 <.001
0.0 12 (0.8) 0 (0.0) 0 (0.0) 12 (0.5)
0.5 364 (24.0) 52 (10.5) 12 (3.9) 428 (18.5)
1.0 583 (38.5) 192 (39.0) 83 (26.9) 858 (37.0)
2.0 408 (26.9) 182 (36.9) 132 (42.7) 722 (31.2)
3.0 148 (9.8) 67 (13.6) 82 (26.5) 297 (12.8)
Hachinski 1.1 (1.4) 1.1 (1.3) 1.3 (1.5) 1.1 (1.4) 2.417‡ .089
GDS 2.2 (2.4) 2.5 (2.8) 2.7 (3.0) 2.3 (2.6) 6.849‡ .001
APOE 4 allele carrier
status
4.008† 2 .135
−4 632 (41.7) 190 (38.5) 112 (36.2) 934 (40.3)
+4 883 (58.3) 303 (61.5) 197 (63.8) 1383 (59.7)
APOE 4 allele
number
5.097† 4 .277 0 632 (41.7) 190 (38.5) 112 (36.3) 934 (40.3)
1 712 (47.0) 236 (47.9) 158 (51.1) 1106 (47.7)
2 171 (11.3) 67 (13.6) 39 (12.6) 277 (12.0)
Abbreviations: AD+P, Alzheimer’s disease plus psychosis; MMSE, Mini-mental state exam; CDR, Clinical dementia rating scale; GDS, Geriatric depression
scale; APOE, Apolipoprotein E.
†Pearson’s Chi-square test: χ2 values are presented.
‡One-way analysis of variance: F values are presented.
Demographic and clinical variables were analyzed for
association with AD+P. Univariate analyses revealed signif-
icant associations for psychosis with sex (female), race (non-
Caucasian), Hispanic ethnicity, primary language (non-
English), lower education, lower MMSE score, higher CDR
score, and higher GDS score (Table 1). There were no
signiﬁcant associations of psychosis with age at presentation,
age of onset of dementia, Hachinski score, APOE 4 allele
carrier status, or the number of APOE 4 alleles (Table 1).
Because psychosis does not typically manifest in early
stages of AD, classifying someone as a “true AD−P” requires
individuals to have reached at least mild to moderate stages
ofdisease [6].Therefore, we conductedfollow-up analyses in
which individuals classiﬁed as AD−Pwere restricted to those
who had at least reached a CDRscore ≥1, N = 1941.In these
univariate analyses, signiﬁcant associations remained for
sex, race, Hispanic ethnicity, primary language, education,
MMSE, CDR, and GDS. Psychosis was now also signiﬁcantly4 International Journal of Alzheimer’s Disease
Table 2: Demographic and clinical characteristics and their association with AD+P with Never Psychotic (AD−P) cases restricted to
CDR ≥ 1.
Variable Psychosis status Total N (%)
or mean (SD) χ2† or F‡ df P value
Never N (%)
or mean (SD)
Single N (%)
or mean (SD)
Multiple/Recurrent
N (%) or mean
(SD)
Age 78.8 (6.8) 79.0 (7.1) 78.3 (7.1) 78.7 (6.9) 0.886‡ .413
Age of onset 73.4 (6.9) 73.4 (7.1) 72.3 (6.9) 73.2 (7.0) 3.094‡ .046
Sex
14.035† 2 .001 Male 529 (46.4) 188 (38.1) 116 (37.5) 833 (42.9)
Female 610 (53.6) 305 (61.9) 193 (62.5) 1108 (57.1)
Race
83.311† 4 <.001 Caucasian 1024 (90.0) 394 (79.9) 216 (70.0) 1634 (84.2)
African-American 87 (7.6) 76 (15.4) 69 (22.3) 232 (12.0)
Other 27 (2.4) 23 (4.7) 24 (7.7) 74 (3.8)
Hispanic
15.243† 2 <.001 No 1069 (93.9) 448 (90.9) 270 (87.4) 1787 (92.1)
Yes 70 (6.1) 45 (9.1) 39 (12.6) 154 (7.9)
Primary language
11.252† 2 .004 English 1070 (93.9) 455 (92.3) 273 (88.3) 1798 (92.6)
Other 69 (6.1) 38 (7.7) 36 (11.7) 143 (7.4)
Education 14.2 (3.6) 13.4 (3.6) 13.0 (4.2) 13.8 (3.7) 16.762‡ <.001
MMSE 16.9 (6.5) 16.8 (7.0) 14.2 (7.1) 16.4 (6.8) 19.386‡ <.001
CDR (global)
186.669† 6 <.001
0.0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0.5 0 (0.0) 52 (10.5) 12 (3.9) 64 (3.3)
1.0 583 (51.2) 192 (39.0) 83 (26.9) 858 (44.2)
2.0 408 (35.8) 182 (36.9) 132 (42.7) 722 (37.2)
3.0 148 (13.0) 67 (13.6) 82 (26.5) 297 (15.3)
Hachinski 1.1 (1.4) 1.1 (1.3) 1.3 (1.5) 1.1 (1.4) 1.864‡ .155
GDS 2.1 (2.3) 2.5 (2.9) 2.7 (3.0) 2.3 (2.6) 6.947‡ .001
APOE 4 allele carrier
status
3.100† 2 .212
−4 471 (41.4) 190 (38.5) 112 (36.2) 773 (39.8)
+4 668 (58.6) 303 (61.5) 197 (63.8) 1168 (60.2)
APOE 4 allele
number
3.502† 4 .478 0 471 (41.3) 190 (38.5) 112 (36.3) 773 (39.8)
1 527 (46.3) 236 (47.9) 158 (51.1) 921 (47.5)
2 141 (12.4) 67 (13.6) 39 (12.6) 247 (12.7)
Abbreviations: AD+P, Alzheimer’s disease plus psychosis; AD−P, Alzheimer’s disease minus psychosis; MMSE, Mini-mental state exam; CDR, Clinical
dementia rating scale; GDS, Geriatric depression scale; APOE, Apolipoprotein E.
†Pearson’s Chi-square test: χ2 values are presented.
‡One-way analysis of variance: F values are presented.
associated with age of onset (younger). Age at presentation,
Hachinski score, APOE 4 allele carrier status, and APOE
4 allele number remained insigniﬁcant for association with
psychosis (Table 2).
Using multinomial regression, increased age at presenta-
tion, lower age of onset of dementia, being non-Caucasian,
lower MMSE, and increased GDS were signiﬁcantly asso-
ciated with both Single and Multiple/Recurrent Psychosis
(Table 3). Lower education was signiﬁcantly associated with
Single, but not Multiple/Recurrent Psychosis. When AD−P
status was restricted to patients with a CDR ≥ 1, race
and GDS remained signiﬁcant predictors of both Single
and Multiple/Recurrent Psychosis (Table 4). Age, age of
onset, and MMSE were signiﬁcantly associated with only
Multiple/Recurrent Psychosis, while education was signiﬁ-
cantly associated with Single Psychosis. Sex, Hispanic origin,International Journal of Alzheimer’s Disease 5
Table 3: Multinomiallogistic regression analysis of Single and Multiple/Recurrent Psychosis.
Psychosis category Variable OR 95% CI Wald χ2 (df = 1) P value
Single
Age 1.053 (1.016, 1.092) 8.083 .004
Age of onset 0.960 (0.926, 0.995) 5.047 .025
Sex 0.799 (0.633, 1.010) 3.515 .061
Race
Caucasian 0.457 (0.233, 0.898) 5.168 .023
African-American 0.834 (0.398, 1.750) 0.230 .632
Othera
Hispanic origin 0.520 (0.263, 1.029) 3.524 .061
Primary language 1.925 (0.901, 4.110) 2.862 .091
Education 0.965 (0.932, 0.999) 4.181 .041
MMSE 0.969 (0.951, 0.987) 10.924 .001
Hachinski 0.972 (0.895, 1.056) 0.437 .508
GDS 1.051 (1.007, 1.096) 5.179 .023
APOE 4 allele number
0 0.778 (0.542, 1.115) 1.867 .172
1 0.815 (0.575, 1.154) 1.329 .249
2a
Multiple/Recurrent
Age 1.078 (1.034, 1.123) 12.485 <.001
Age of onset 0.914 (0.876, 0.953) 17.716 <.001
Sex 0.847 (0.631, 1.136) 1.233 .267
Race
Caucasian 0.311 (0.151, 0.642) 9.977 .002
African-American 1.008 (0.455, 2.232) 0.000 .985
Othera
Hispanic origin 0.457 (0.207, 1.007) 3.774 .052
Primary language 1.157 (0.495, 2.703) 0.113 .736
Education 0.974 (0.935, 1.014) 1.654 .198
MMSE 0.911 (0.892, 0.931) 71.322 <.001
Hachinski 1.039 (0.948, 1.140) 0.673 .412
GDS 1.077 (1.025, 1.132) 8.489 .004
APOE 4 allele number
0 0.817 (0.518, 1.290) 0.751 .386
1 0.999 (0.647, 1.541) 0.000 .996
2a
Abbreviations: MMSE, Mini-mental state exam; GDS, Geriatric depression scale; APOE, Apolipoprotein E.
aReference group.
primary language, Hachinski score, and APOE 4 allele
number were not signiﬁcantly associated with psychosis in
either analysis.
The UDS also requires reporting on several vascular
burden and comorbidity variables, such as hypertension.
We did univariate analyses of 12 such variables (see Sup-
plementary Table 1 in Supplementary Material available
online at doi:10.4061/2011/926597). Only hypertension and
diabetes were signiﬁcantly associated with psychosis. When
the analyses were restricted to patients who has at least
reached a CDR score ≥1, signiﬁcance for diabetes remained,
but signiﬁcance for hypertension was lost (Supplementary
Table 2). In multinomial regression analyses in which
hypertension and diabetes were entered as covariates, along
with age, age of onset, sex, race, ethnicity, primary language,
education, MMSE, GDS, Hachinski, and APOE, neither was
signiﬁcantly associated with any psychosis measure. The
association of all other variables with psychosis remained
unchanged (data not shown).
4.Discussion
This is the largest study to date to look at the association
between APOE 4a n dA D + P .W ew e r ea b l et oe x a m i n e
the associations of APOE and other variables with both any
occurrence of psychotic symptoms and with progressively
more heritable (and therefore perhaps more biologically
relevant) psychotic phenotypes deﬁned by the presence of
multiple and/or recurrent psychotic symptoms and with
a more stringently restrictive deﬁnition of nonpsychotic
AD cases. Neither APOE 4 carrier status nor APOE 4
allele number was associated with psychosis in any analysis.6 International Journal of Alzheimer’s Disease
Table 4: Multinomial logistic regression analysis of Single and Multiple/Recurrent Psychosis when Never Psychotic (AD−P) cases were
restricted to CDR ≥ 1.
Psychosis category Variable OR 95% CI Wald χ2 (df = 1) P value
Single
Age 1.022 (0.985, 1.061) 1.326 .250
Age of onset 0.980 (0.944, 1.017) 1.178 .278
Sex 0.833 (0.653, 1.063) 2.151 .143
Race
Caucasian 0.482 (0.236, 0.983) 4.028 .045
African-American 1.046 (0.476, 2.297) 0.013 .911
Othera
Hispanic origin 0.590 (0.295, 1.178) 2.234 .135
Primary language 1.699 (0.787, 3.670) 1.822 .177
Education 0.958 (0.924, 0.993) 5.583 .018
MMSE 1.016 (0.995, 1.036) 2.221 .136
Hachinski 0.966 (0.886, 1.053) 0.605 .437
GDS 1.053 (1.007, 1.101) 5.160 .023
APOE 4 allele number
0 0.858 (0.592, 1.243) 0.655 .418
1 0.917 (0.641, 1.313) 0.223 .637
2a
Multiple/Recurrent
Age 1.052 (1.009, 1.098) 5.543 .019
Age of onset 0.929 (0.889, 0.969) 11.458 .001
Sex 0.876 (0.649, 1.182) 0.750 .387
Race
Caucasian 0.326 (0.153, 0.695) 8.438 .004
African-American 1.204 (0.523, 2.769) 0.190 .663
Othera
Hispanic origin 0.522 (0.237, 1.151) 2.597 .107
Primary language 1.030 (0.440, 2.408) 0.005 .946
Education 0.969 (0.930, 1.010) 2.274 .132
MMSE 0.947 (0.925, 0.968) 22.376 <.001
Hachinski 1.034 (0.942, 1.136) 0.499 .480
GDS 1.080 (1.026, 1.137) 8.692 .003
APOE 4 allele number
0 0.883 (0.557, 1.398) 0.283 .595
1 1.087 (0.702, 1.685) 0.140 .709
2a
Abbreviations: AD−P, Alzheimer’s disease minus psychosis;MMSE, Mini-mental state exam; GDS, Geriatric depression scale; APOE, Apolipoprotein E.
aReference group.
S i m i l a r l y ,t h ed e g r e eo fv a s c u l a rd i s e a s ea sr a t e do nt h e
Hachinski scale was not associated with AD+P in any anal-
ysis. Our analysis of these multiple deﬁnitions of AD+P also
revealed other patterns. Greater cognitive impairment and
greater depressive symptoms were associated with increased
incidence of psychosis across multiple analyses, with the
strongest associations observed with Multiple/Recurrent
Psychosis. A similar pattern of association was seen for
Caucasian race, although it was protective against AD+P.
Other variables demonstrated less consistent associations,
emerging (e.g., age and age of onset of AD), or disappearing
(sex, Hispanic ethnicity, primary language), after controlling
for the eﬀects of other variables in multivariate analyses.
Finally, years of education showed associations with AD+P
in both univariate and multivariate analyses, but not in the
latter with the Multiple/Recurrent phenotype.
Many studies have looked at the association of APOE
4 with AD+P, with conﬂicting, albeit largely negative,
results [12]. A number of possible reasons might have
contributed to these contradictory ﬁndings, including the
variability in sample size across studies, heterogeneity of AD
subjects (with regard to early versus late stages of AD and
early- or late-onset AD), and diﬀerent methods of psychosis
assessment and classiﬁcation. Adding to the inconsistencies
across studies, prior studies varied regarding whether they
analyzed APOE genotype, 4 allele number, or 4 carrierInternational Journal of Alzheimer’s Disease 7
status and the extent to which they included relevant clinical
and demographic information in multivariate models.
We were able to overcome many of these problems by
utilizing the NACC UDS to evaluate the largest sample of
subjects studied for the association of APOE with AD+P to
date.Subjectsfrom24ADCsacrossthecountrywereassessed
using a standardized battery allowing for multivariate anal-
yses including a number of potentially relevant clinical and
demographic measures in essentially all subjects. Further,
guided by data indicating the stage-dependent emergence of
psychotic symptoms during AD [6, 20] and the increased
heritability of an AD+P phenotype deﬁned by the presence
of multiple and/or recurrent symptoms [6, 7], we were able
to assess the association of APOE with a restrictive deﬁnition
of AD+P likely to be enriched for association with causal
genetic variants.
Using these approacheswe found no evidencethat APOE
4 is associated with AD+P. It is possible from the small
magnitude of the odds ratios observed in our study that a
signiﬁcant association would be observed in a much larger
sample. However, the current results are consistent with the
majority ofthe priorevidence,in which only nine of22prior
studies,comprisingmore than5,200subjectswithAD,found
any evidence of signiﬁcant association [12]. Furthermore,
we showed previously that the time from entry into our
clinicto theonset ofpsychosis was not associated with APOE
genotypes,lendingadditionalsupporttothecurrentﬁndings
[21].Thus,themostlikelyconclusionisthatAPOE4carrier
status and allele number are not associated with psychosis in
a population of patients with late-onset Alzheimer’s disease.
AswithAPOE,thecurrentdatasetandanalyticapproach
can also shed some light on the conﬂicting results of prior
studies which have examined the association of AD+P with
other clinical and demographic variables. As summarized
in a recent review by Ropacki and Jeste [1], AD+P was
signiﬁcantly associated with older age in 12/25 studies,
with age of onset in 5/12 studies (older in 4/5, younger
in 1/5), with gender in 7/24 studies (male in 3/7, female
in 4/7), with African-American race in 5/7 studies, and
with lower education in 4/17 studies. More recent studies
have found a signiﬁcant association between AD+P and the
severity of depressive symptoms [6, 22–24]. Our ﬁndings
would suggest that the associations with AD+P of age, age
of onset of dementia, non-Caucasian race, and depressive
symptom severity represent “true positives” while those
for sex, ethnicity, and primary language are explained by
confounding with other variables.
One of the most consistent correlates of AD+P in prior
studies is greater burden of cognitive impairment, whether
measured as degree of cognitive impairment at time of
p s y c h o s i so ra sm o r er a p i dc o g n i t i v ed e c l i n e[ 1, 10, 25].
Our current ﬁndings are congruent with the former of these
prior observations; however, we did not measure the rate of
cognitive decline in this study because of the limited number
of subjects who have had follow-up assessments entered to
date. The mechanisms underlying the association between
greater cognitive impairment and AD+P are not known, but
the current analysis suggests that one potential mediator,
increased vascular burden [26], as measured by a global
summary, the Hachinski, does not explain the association.,
Wefollowed thisupbyanalysisofdirectmeasures ofvascular
risk factors and cerebrovascular disease. Of the 12 UDS
variables, only history of hypertension and diabetes achieved
marginal signiﬁcant associations with AD+P in univariate
analyses, In multivariate analysis the signiﬁcance for both
was lost. Therefore, the most conservative interpretation is
that increased vascular burden is not associated with AD+P.
Amongst the other demographic variables that we tested,
the ﬁnding that non-Caucasian (predominantly African-
American) subjects are more likely to develop psychosis
during the progression of AD deserves some comment. It
is not clear if this association is due to diﬀerences between
ethnic groups in allele frequencies of potential AD+P risk
genes [27] or if being rated as positive for psychotic symp-
toms, such as persecutory delusions, represents culturally
or socioeconomically biased measures of psychosis or refer-
ral bias within minority communities. Without having a
representative sample of minorities from all socioeconomic
backgrounds, it will be impossible to make this distinction.
Regardless, the implication for studies of genetic association
in AD+P is that non-Caucasian subjects should be evaluated
separately from Caucasian populations and combined in
analyses only if heterogeneity is not observed.
T h ep r e s e n c eo f4 alleles of APOE is currently the
strongest genetic determinant for late-onset AD, a fact un-
derlined by the ﬁndings in most genome-wide association
studies oflate-onset AD,which have “rediscovered” the asso-
ciation with APOE (http://www.alzgene.org/). We provide
evidence that a heritable subtype of AD, deﬁned by the
presence ofmultiple or recurrent psychotic symptoms, is not
associated with APOE 4. As the discovery of non-APOE
genetic variation contributing to the risk of late-onset AD
remains a high priority, one approach to enriching cohorts
toenhancesuccessfuldiscoverymaybetoexamine theAD+P
phenotype.
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